References
- Bitner RS, Bunnelle WH, Anderson DJ, et al. (2007). Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27:10578–87
- Bitner RS, Bunnelle WH, Decker MW, et al. (2010). In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer’s disease. J Pharmacol Exp Ther 334:875–86
- Curzon P, Anderson DJ, Nikkel AL, et al. (2006). Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 410:15–19
- Dani JA, Bertrand D. (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729
- Diamond S, Boer J, Maduskuie TP Jr, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–85
- Houston JB, Kenworthy KE. (2000). In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis–Menten model. Drug Metab Dispos 28:246–54
- Komura H, Iwaki M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775–800
- Malysz J, Anderson DJ, Gronlien JH, et al. (2010). In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther 334:863–74
- Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94
- Mazurov A, Hauser T, Miller CH. (2006). Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 13:1567–84
- Mutlib AE, Gerson RJ, Meunier PC, et al. (2000). The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 169:102–13
- Othman AA, Lenz RA, Zhang J, et al. (2010). Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J Clin Pharmacol 51:512–26
- Pasanen M. (2004). Species differences in CYP enzymes. In: Angosto MC, Gomez-Lechon MJ, eds. Citocromo P450. Madrid: Instituto De Espana, Real Academia Macional De Farmacia Madrid, 63–90
- Shaffer CL, Gunduz M, Ryder TF, O’Connell TN. (2010). Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition. Drug Metab Dispos 38:292–301
- Shaffer CL, Gunduz M, Scialis RJ, Fang AF. (2007). Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans. Drug Metab Dispos 35:1188–95
- Shilliday FB, Walker DP, Gu C, et al. (2010). Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett 4:162–72
- Tong Z, Chandrasekaran A, DeMaio W, et al. (2010). Species differences in the formation of vabicaserin carbamoyl glucuronide. Drug Metab Dispos 38:581–90
- Zhou D, Zhang M, Ye X, et al. (2011). In vitro metabolism of alpha7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite. Xenobiotica 41:232–42